B-type Natriuretic Peptide vs Adrenomedullin
Side-by-Side Comparison
| Attribute | Bnp | Adrenomedullin |
|---|---|---|
| Category | Cardiovascular / Natriuretic | Cardiovascular / Vasoactive |
| Mechanism | BNP binds to natriuretic peptide receptor A (NPR-A), activating the intracellular guanylyl cyclase domain and increasing cGMP production. | Adrenomedullin signals through the calcitonin receptor-like receptor (CLR) complexed with receptor activity-modifying protein 2 or 3 (RAMP2/RAMP3), forming the AM1 and AM2 receptors respectively. |
| Evidence Rating | B — Established Biomarker / Therapeutic Basis | D — Biomarker / Early Research |
| Clinical Status | Established diagnostic biomarker for heart failure. Recombinant form (nesiritide) is FDA-approved for acute decompensated heart failure. | Research stage. MR-proADM used as prognostic biomarker in sepsis and heart failure. No approved therapeutic use of adrenomedullin peptide. |
| Safety Profile | Endogenous BNP is a normal physiological hormone with no inherent toxicity; As a biomarker test, BNP/NT-proBNP assays carry no direct safety risks | No human safety data from controlled therapeutic trials; Experimental IV infusion in healthy volunteers caused hypotension and reflex tachycardia |
| Route | N/A (diagnostic biomarker) | Intravenous infusion (research only) |
| Dose Range | N/A | 10–50 ng/kg/min in human physiological studies |
| Frequency | N/A | Continuous or bolus infusion |
| Molecular Weight | ~3464 g/mol | ~6028 g/mol |
| Half-Life | ~20 minutes (BNP); ~120 minutes (NT-proBNP) | ~22 minutes (plasma) |
Overview
B-type Natriuretic Peptide and Adrenomedullin are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
B-type Natriuretic Peptide — Mechanism & Evidence
B-type natriuretic peptide (BNP) is a 32-amino-acid cardiac hormone (MW ~3464 g/mol) secreted primarily by ventricular cardiomyocytes in response to myocardial wall stress from volume overload or pressure overload. It is both a critical diagnostic biomarker for heart failure (BNP/NT-proBNP assays) and the basis for the therapeutic agent nesiritide (recombinant BNP). Originally identified in porcine brain tissue, hence the historical name "brain natriuretic peptide."
Key claims: BNP/NT-proBNP levels accurately diagnose heart failure; BNP-guided therapy may improve heart failure outcomes; BNP levels have prognostic value in heart failure and acute coronary syndromes.
Adrenomedullin — Mechanism & Evidence
Adrenomedullin is a 52-amino-acid vasodilatory peptide (MW ~6028 g/mol) originally isolated from human pheochromocytoma tissue. It is widely expressed in the cardiovascular system, lungs, kidneys, and adrenal glands, with potent vasodilatory, natriuretic, and cardioprotective properties. It is currently investigated as a biomarker (MR-proADM) for sepsis and heart failure prognosis, with no approved therapeutic use of the peptide itself.
Key claims: MR-proADM is a strong prognostic biomarker in sepsis; MR-proADM predicts mortality in acute heart failure; Adrenomedullin has potent vasodilatory effects in humans.
Shared Research Applications
Both peptides are studied for: Cardiovascular Research.
B-type Natriuretic Peptide is also researched for: Heart Failure Diagnosis, Cardiac Biomarker.
Adrenomedullin is also researched for: Sepsis Prognostication, Heart Failure Biomarker.
Safety Considerations
B-type Natriuretic Peptide: Endogenous BNP is a normal physiological hormone with no inherent toxicity As a biomarker test, BNP/NT-proBNP assays carry no direct safety risks Exogenous recombinant BNP (nesiritide) safety profile includes hypotension and potential renal effects (see nesiritide entry)
Adrenomedullin: No human safety data from controlled therapeutic trials Experimental IV infusion in healthy volunteers caused hypotension and reflex tachycardia Theoretical risk of excessive vasodilation and hemodynamic instability
